HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
35Pharma Inc · NCT07123779
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 1, Phase 2
- Target enrollment
- 126
- US sites recruiting
- 2
- Study start
- September 2026
- Record last updated
- September 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
Being studied: HS235; Placebo
Conditions: Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Participants are eligible to be included in the study only if they meet at least all the following criteria:
- Male or female, ≥ 18 years of age.
- [Sub-population A only - using a remote PAP sensor]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.
Hemodynamic evidence of PH with
- mPAP ≥ 25 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
- dPAP ≥ 15 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
- Hemodynamic evidence of pre-capillary PH based on presence of PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU obtained on most recent RHC obtained prior to screening.
- [Sub-population B only - without a remote PAP sensor]
Hemodynamic evidence of Cpc-PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
- PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU, and
- mPAP > 20 mmHg, and
- PAWP > 15 mmHg but \< 30 mmHg, and
- dPAP ≥ 15 mmHg.
- Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening..
- New York Heart Association (NYHA) class II or III heart failure symptoms.
- Stable diuretic regimen during the screening period.
- Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening.
- 6-minute walking distance (6MWD) ≥ 100 m at screening.
- Body mass index ≥ 25 to ≤ 50 kg/m2 and Body weight ≤140 kg.
- Ability to adhere to study visit schedule and understand and comply with all protocol requirements.
Exclusion Criteria
- Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
- Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.
- Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.
- Planned cardiovascular revascularization or planned implantation of CRT device.
- History of heart transplant or on heart transplant list.
- History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.
- Systemic hypotension or uncontrolled systemic hypertension.
- History of Pericardial constriction or hypertrophic cardiomyopathy.
- History of significant valvular stenosis or regurgitation.
- Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or untreated mild obstructive sleep apnea (OSA).
Recruiting US locations
Investigational Site-105
Kansas City, MO 64111
Investigational Site-101
Greenville, SC 29605
Study contacts (from the official record)
- US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
- EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Similar studies in Missouri
All weight loss studies in Missouri →- RecruitingHealthy volunteersOvernight stay mentioned
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Bettina Mittendorfer
- Location
- Columbia, MO
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersOvernight stay mentioned
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Bettina Mittendorfer
- Location
- Columbia, MO
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersEarly Phase 1
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
University of Missouri-Columbia
- Location
- Columbia, MO
- Eligibility basics
- Ages 18–45
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Chesterfield, MO + 55 other US sites
- Eligibility basics
- Ages 18–79